

# Neurometabolic Disorders Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/N65C37B396A8EN.html>

Date: April 2022

Pages: 103

Price: US\$ 3,250.00 (Single User License)

ID: N65C37B396A8EN

## Abstracts

Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.

This report contains market size and forecasts of Neurometabolic Disorders in Global, including the following market information:

Global Neurometabolic Disorders Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Neurometabolic Disorders market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Gaucher's Disease Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neurometabolic Disorders include Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals, Biosidus, Greenovation Biotech, UAB Proforma, Dong-A Socio Group, ExSAR Corporation and Lixte Biotechnology, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurometabolic Disorders

companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neurometabolic Disorders Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Neurometabolic Disorders Market Segment Percentages, by Type, 2021 (%)

Gaucher's Disease

Fabry Disease

Pompe Disease

Mucopolysaccharidosis VI

Other

Global Neurometabolic Disorders Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Neurometabolic Disorders Market Segment Percentages, by Application, 2021 (%)

Oral

Parenteral

Global Neurometabolic Disorders Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Neurometabolic Disorders Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

## South America

Brazil

Argentina

Rest of South America

## Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neurometabolic Disorders revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Neurometabolic Disorders revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Amicus Therapeutics

ISU Abxis

JCR Pharmaceuticals

Biosidus

Greenovation Biotech

UAB Proforma

Dong-A Socio Group

ExSAR Corporation

Lixte Biotechnology

Neuraltus Pharmaceuticals

Protalix

Pharming Group

Protalix BioTherapeutics

Amicus

Biomarin

Genzyme

Shire

Greencross

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Neurometabolic Disorders Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Neurometabolic Disorders Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL NEUROMETABOLIC DISORDERS OVERALL MARKET SIZE**

- 2.1 Global Neurometabolic Disorders Market Size: 2021 VS 2028
- 2.2 Global Neurometabolic Disorders Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top Neurometabolic Disorders Players in Global Market
- 3.2 Top Global Neurometabolic Disorders Companies Ranked by Revenue
- 3.3 Global Neurometabolic Disorders Revenue by Companies
- 3.4 Top 3 and Top 5 Neurometabolic Disorders Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Neurometabolic Disorders Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Neurometabolic Disorders Players in Global Market
  - 3.6.1 List of Global Tier 1 Neurometabolic Disorders Companies
  - 3.6.2 List of Global Tier 2 and Tier 3 Neurometabolic Disorders Companies

### **4 MARKET SIGHTS BY PRODUCT**

#### 4.1 Overview

4.1.1 by Type - Global Neurometabolic Disorders Market Size Markets, 2021 & 2028

4.1.2 Gaucher's Disease

4.1.3 Fabry Disease

4.1.4 Pompe Disease

4.1.5 Mucopolysaccharidosis VI

4.1.6 Other

#### 4.2 By Type - Global Neurometabolic Disorders Revenue & Forecasts

4.2.1 By Type - Global Neurometabolic Disorders Revenue, 2017-2022

4.2.2 By Type - Global Neurometabolic Disorders Revenue, 2023-2028

4.2.3 By Type - Global Neurometabolic Disorders Revenue Market Share, 2017-2028

### 5 SIGHTS BY APPLICATION

#### 5.1 Overview

5.1.1 By Application - Global Neurometabolic Disorders Market Size, 2021 & 2028

5.1.2 Oral

5.1.3 Parenteral

#### 5.2 By Application - Global Neurometabolic Disorders Revenue & Forecasts

5.2.1 By Application - Global Neurometabolic Disorders Revenue, 2017-2022

5.2.2 By Application - Global Neurometabolic Disorders Revenue, 2023-2028

5.2.3 By Application - Global Neurometabolic Disorders Revenue Market Share, 2017-2028

### 6 SIGHTS BY REGION

6.1 By Region - Global Neurometabolic Disorders Market Size, 2021 & 2028

#### 6.2 By Region - Global Neurometabolic Disorders Revenue & Forecasts

6.2.1 By Region - Global Neurometabolic Disorders Revenue, 2017-2022

6.2.2 By Region - Global Neurometabolic Disorders Revenue, 2023-2028

6.2.3 By Region - Global Neurometabolic Disorders Revenue Market Share, 2017-2028

#### 6.3 North America

6.3.1 By Country - North America Neurometabolic Disorders Revenue, 2017-2028

6.3.2 US Neurometabolic Disorders Market Size, 2017-2028

6.3.3 Canada Neurometabolic Disorders Market Size, 2017-2028

6.3.4 Mexico Neurometabolic Disorders Market Size, 2017-2028

#### 6.4 Europe

6.4.1 By Country - Europe Neurometabolic Disorders Revenue, 2017-2028

6.4.2 Germany Neurometabolic Disorders Market Size, 2017-2028

6.4.3 France Neurometabolic Disorders Market Size, 2017-2028

6.4.4 U.K. Neurometabolic Disorders Market Size, 2017-2028

6.4.5 Italy Neurometabolic Disorders Market Size, 2017-2028

6.4.6 Russia Neurometabolic Disorders Market Size, 2017-2028

6.4.7 Nordic Countries Neurometabolic Disorders Market Size, 2017-2028

6.4.8 Benelux Neurometabolic Disorders Market Size, 2017-2028

## 6.5 Asia

6.5.1 By Region - Asia Neurometabolic Disorders Revenue, 2017-2028

6.5.2 China Neurometabolic Disorders Market Size, 2017-2028

6.5.3 Japan Neurometabolic Disorders Market Size, 2017-2028

6.5.4 South Korea Neurometabolic Disorders Market Size, 2017-2028

6.5.5 Southeast Asia Neurometabolic Disorders Market Size, 2017-2028

6.5.6 India Neurometabolic Disorders Market Size, 2017-2028

## 6.6 South America

6.6.1 By Country - South America Neurometabolic Disorders Revenue, 2017-2028

6.6.2 Brazil Neurometabolic Disorders Market Size, 2017-2028

6.6.3 Argentina Neurometabolic Disorders Market Size, 2017-2028

## 6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Neurometabolic Disorders Revenue, 2017-2028

6.7.2 Turkey Neurometabolic Disorders Market Size, 2017-2028

6.7.3 Israel Neurometabolic Disorders Market Size, 2017-2028

6.7.4 Saudi Arabia Neurometabolic Disorders Market Size, 2017-2028

6.7.5 UAE Neurometabolic Disorders Market Size, 2017-2028

## 7 PLAYERS PROFILES

### 7.1 Amicus Therapeutics

7.1.1 Amicus Therapeutics Corporate Summary

7.1.2 Amicus Therapeutics Business Overview

7.1.3 Amicus Therapeutics Neurometabolic Disorders Major Product Offerings

7.1.4 Amicus Therapeutics Neurometabolic Disorders Revenue in Global Market (2017-2022)

7.1.5 Amicus Therapeutics Key News

### 7.2 ISU Abxis

7.2.1 ISU Abxis Corporate Summary

7.2.2 ISU Abxis Business Overview

7.2.3 ISU Abxis Neurometabolic Disorders Major Product Offerings



- 7.2.4 ISU Abxis Neurometabolic Disorders Revenue in Global Market (2017-2022)
- 7.2.5 ISU Abxis Key News
- 7.3 JCR Pharmaceuticals
  - 7.3.1 JCR Pharmaceuticals Corporate Summary
  - 7.3.2 JCR Pharmaceuticals Business Overview
  - 7.3.3 JCR Pharmaceuticals Neurometabolic Disorders Major Product Offerings
  - 7.3.4 JCR Pharmaceuticals Neurometabolic Disorders Revenue in Global Market (2017-2022)
  - 7.3.5 JCR Pharmaceuticals Key News
- 7.4 Biosidus
  - 7.4.1 Biosidus Corporate Summary
  - 7.4.2 Biosidus Business Overview
  - 7.4.3 Biosidus Neurometabolic Disorders Major Product Offerings
  - 7.4.4 Biosidus Neurometabolic Disorders Revenue in Global Market (2017-2022)
  - 7.4.5 Biosidus Key News
- 7.5 Greenovation Biotech
  - 7.5.1 Greenovation Biotech Corporate Summary
  - 7.5.2 Greenovation Biotech Business Overview
  - 7.5.3 Greenovation Biotech Neurometabolic Disorders Major Product Offerings
  - 7.5.4 Greenovation Biotech Neurometabolic Disorders Revenue in Global Market (2017-2022)
  - 7.5.5 Greenovation Biotech Key News
- 7.6 UAB Proforma
  - 7.6.1 UAB Proforma Corporate Summary
  - 7.6.2 UAB Proforma Business Overview
  - 7.6.3 UAB Proforma Neurometabolic Disorders Major Product Offerings
  - 7.6.4 UAB Proforma Neurometabolic Disorders Revenue in Global Market (2017-2022)
  - 7.6.5 UAB Proforma Key News
- 7.7 Dong-A Socio Group
  - 7.7.1 Dong-A Socio Group Corporate Summary
  - 7.7.2 Dong-A Socio Group Business Overview
  - 7.7.3 Dong-A Socio Group Neurometabolic Disorders Major Product Offerings
  - 7.7.4 Dong-A Socio Group Neurometabolic Disorders Revenue in Global Market (2017-2022)
  - 7.7.5 Dong-A Socio Group Key News
- 7.8 ExSAR Corporation
  - 7.8.1 ExSAR Corporation Corporate Summary
  - 7.8.2 ExSAR Corporation Business Overview
  - 7.8.3 ExSAR Corporation Neurometabolic Disorders Major Product Offerings

7.8.4 ExSAR Corporation Neurometabolic Disorders Revenue in Global Market (2017-2022)

7.8.5 ExSAR Corporation Key News

7.9 Lixte Biotechnology

7.9.1 Lixte Biotechnology Corporate Summary

7.9.2 Lixte Biotechnology Business Overview

7.9.3 Lixte Biotechnology Neurometabolic Disorders Major Product Offerings

7.9.4 Lixte Biotechnology Neurometabolic Disorders Revenue in Global Market (2017-2022)

7.9.5 Lixte Biotechnology Key News

7.10 Neuraltus Pharmaceuticals

7.10.1 Neuraltus Pharmaceuticals Corporate Summary

7.10.2 Neuraltus Pharmaceuticals Business Overview

7.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Major Product Offerings

7.10.4 Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue in Global Market (2017-2022)

7.10.5 Neuraltus Pharmaceuticals Key News

7.11 Protalix

7.11.1 Protalix Corporate Summary

7.11.2 Protalix Business Overview

7.11.3 Protalix Neurometabolic Disorders Major Product Offerings

7.11.4 Protalix Neurometabolic Disorders Revenue in Global Market (2017-2022)

7.11.5 Protalix Key News

7.12 Pharming Group

7.12.1 Pharming Group Corporate Summary

7.12.2 Pharming Group Business Overview

7.12.3 Pharming Group Neurometabolic Disorders Major Product Offerings

7.12.4 Pharming Group Neurometabolic Disorders Revenue in Global Market (2017-2022)

7.12.5 Pharming Group Key News

7.13 Protalix BioTherapeutics

7.13.1 Protalix BioTherapeutics Corporate Summary

7.13.2 Protalix BioTherapeutics Business Overview

7.13.3 Protalix BioTherapeutics Neurometabolic Disorders Major Product Offerings

7.13.4 Protalix BioTherapeutics Neurometabolic Disorders Revenue in Global Market (2017-2022)

7.13.5 Protalix BioTherapeutics Key News

7.14 Amicus

7.14.1 Amicus Corporate Summary

- 7.14.2 Amicus Business Overview
- 7.14.3 Amicus Neurometabolic Disorders Major Product Offerings
- 7.14.4 Amicus Neurometabolic Disorders Revenue in Global Market (2017-2022)
- 7.14.5 Amicus Key News
- 7.15 Biomarin
  - 7.15.1 Biomarin Corporate Summary
  - 7.15.2 Biomarin Business Overview
  - 7.15.3 Biomarin Neurometabolic Disorders Major Product Offerings
  - 7.15.4 Biomarin Neurometabolic Disorders Revenue in Global Market (2017-2022)
  - 7.15.5 Biomarin Key News
- 7.16 Genzyme
  - 7.16.1 Genzyme Corporate Summary
  - 7.16.2 Genzyme Business Overview
  - 7.16.3 Genzyme Neurometabolic Disorders Major Product Offerings
  - 7.16.4 Genzyme Neurometabolic Disorders Revenue in Global Market (2017-2022)
  - 7.16.5 Genzyme Key News
- 7.17 Shire
  - 7.17.1 Shire Corporate Summary
  - 7.17.2 Shire Business Overview
  - 7.17.3 Shire Neurometabolic Disorders Major Product Offerings
  - 7.17.4 Shire Neurometabolic Disorders Revenue in Global Market (2017-2022)
  - 7.17.5 Shire Key News
- 7.18 Greencross
  - 7.18.1 Greencross Corporate Summary
  - 7.18.2 Greencross Business Overview
  - 7.18.3 Greencross Neurometabolic Disorders Major Product Offerings
  - 7.18.4 Greencross Neurometabolic Disorders Revenue in Global Market (2017-2022)
  - 7.18.5 Greencross Key News

## **8 CONCLUSION**

## **9 APPENDIX**

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Neurometabolic Disorders Market Opportunities & Trends in Global Market

Table 2. Neurometabolic Disorders Market Drivers in Global Market

Table 3. Neurometabolic Disorders Market Restraints in Global Market

Table 4. Key Players of Neurometabolic Disorders in Global Market

Table 5. Top Neurometabolic Disorders Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Neurometabolic Disorders Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Neurometabolic Disorders Revenue Share by Companies, 2017-2022

Table 8. Global Companies Neurometabolic Disorders Product Type

Table 9. List of Global Tier 1 Neurometabolic Disorders Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Neurometabolic Disorders Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Neurometabolic Disorders Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Neurometabolic Disorders Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Neurometabolic Disorders Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Neurometabolic Disorders Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Neurometabolic Disorders Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Neurometabolic Disorders Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Neurometabolic Disorders Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Neurometabolic Disorders Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Neurometabolic Disorders Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Neurometabolic Disorders Revenue, (US\$, Mn),

2023-2028

Table 22. By Country - Europe Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Neurometabolic Disorders Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Neurometabolic Disorders Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Neurometabolic Disorders Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Neurometabolic Disorders Revenue, (US\$, Mn), 2023-2028

Table 30. Amicus Therapeutics Corporate Summary

Table 31. Amicus Therapeutics Neurometabolic Disorders Product Offerings

Table 32. Amicus Therapeutics Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 33. ISU Abxis Corporate Summary

Table 34. ISU Abxis Neurometabolic Disorders Product Offerings

Table 35. ISU Abxis Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 36. JCR Pharmaceuticals Corporate Summary

Table 37. JCR Pharmaceuticals Neurometabolic Disorders Product Offerings

Table 38. JCR Pharmaceuticals Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 39. Biosidus Corporate Summary

Table 40. Biosidus Neurometabolic Disorders Product Offerings

Table 41. Biosidus Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 42. Greenovation Biotech Corporate Summary

Table 43. Greenovation Biotech Neurometabolic Disorders Product Offerings

Table 44. Greenovation Biotech Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 45. UAB Proforma Corporate Summary

Table 46. UAB Proforma Neurometabolic Disorders Product Offerings

Table 47. UAB Proforma Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 48. Dong-A Socio Group Corporate Summary

Table 49. Dong-A Socio Group Neurometabolic Disorders Product Offerings

Table 50. Dong-A Socio Group Neurometabolic Disorders Revenue (US\$, Mn),

(2017-2022)

Table 51. ExSAR Corporation Corporate Summary

Table 52. ExSAR Corporation Neurometabolic Disorders Product Offerings

Table 53. ExSAR Corporation Neurometabolic Disorders Revenue (US\$, Mn),  
(2017-2022)

Table 54. Lixte Biotechnology Corporate Summary

Table 55. Lixte Biotechnology Neurometabolic Disorders Product Offerings

Table 56. Lixte Biotechnology Neurometabolic Disorders Revenue (US\$, Mn),  
(2017-2022)

Table 57. Neuraltus Pharmaceuticals Corporate Summary

Table 58. Neuraltus Pharmaceuticals Neurometabolic Disorders Product Offerings

Table 59. Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue (US\$, Mn),  
(2017-2022)

Table 60. Protalix Corporate Summary

Table 61. Protalix Neurometabolic Disorders Product Offerings

Table 62. Protalix Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 63. Pharming Group Corporate Summary

Table 64. Pharming Group Neurometabolic Disorders Product Offerings

Table 65. Pharming Group Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 66. Protalix BioTherapeutics Corporate Summary

Table 67. Protalix BioTherapeutics Neurometabolic Disorders Product Offerings

Table 68. Protalix BioTherapeutics Neurometabolic Disorders Revenue (US\$, Mn),  
(2017-2022)

Table 69. Amicus Corporate Summary

Table 70. Amicus Neurometabolic Disorders Product Offerings

Table 71. Amicus Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 72. Biomarin Corporate Summary

Table 73. Biomarin Neurometabolic Disorders Product Offerings

Table 74. Biomarin Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 75. Genzyme Corporate Summary

Table 76. Genzyme Neurometabolic Disorders Product Offerings

Table 77. Genzyme Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 78. Shire Corporate Summary

Table 79. Shire Neurometabolic Disorders Product Offerings

Table 80. Shire Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)

Table 81. Greencross Corporate Summary

Table 82. Greencross Neurometabolic Disorders Product Offerings

Table 83. Greencross Neurometabolic Disorders Revenue (US\$, Mn), (2017-2022)



## List Of Figures

### LIST OF FIGURES

- Figure 1. Neurometabolic Disorders Segment by Type in 2021
- Figure 2. Neurometabolic Disorders Segment by Application in 2021
- Figure 3. Global Neurometabolic Disorders Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Neurometabolic Disorders Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Neurometabolic Disorders Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Neurometabolic Disorders Revenue in 2021
- Figure 8. By Type - Global Neurometabolic Disorders Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Neurometabolic Disorders Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Neurometabolic Disorders Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Neurometabolic Disorders Revenue Market Share, 2017-2028
- Figure 12. US Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Neurometabolic Disorders Revenue Market Share, 2017-2028
- Figure 16. Germany Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Neurometabolic Disorders Revenue Market Share, 2017-2028
- Figure 24. China Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028
- Figure 28. India Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Neurometabolic Disorders Revenue Market Share, 2017-2028

Figure 30. Brazil Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Neurometabolic Disorders Revenue Market Share, 2017-2028

Figure 33. Turkey Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Neurometabolic Disorders Revenue, (US\$, Mn), 2017-2028

Figure 37. Amicus Therapeutics Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. ISU Abxis Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. JCR Pharmaceuticals Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Biosidus Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Greenovation Biotech Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. UAB Proforma Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Dong-A Socio Group Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. ExSAR Corporation Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Lixte Biotechnology Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Protalix Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Pharming Group Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Protalix BioTherapeutics Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Amicus Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Biomarin Neurometabolic Disorders Revenue Year Over Year Growth (US\$,



Mn) & (2017-2022)

Figure 52. Genzyme Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 53. Shire Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. Greencross Neurometabolic Disorders Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: Neurometabolic Disorders Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/N65C37B396A8EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N65C37B396A8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970